Noscira's novel Alzheimer's drug shows promise in Phase II
This article was originally published in Scrip
Executive Summary
Noscira's novel Alzheimer's disease-modifying oral drug candidate Nypta (tideglusib; NP-12) has achieved positive results in a Phase IIa study presented at the recent International Conference on Alzheimer's disease (ICAD) in Hawaii.